Literature DB >> 10654357

Eurotransplant randomized multicenter kidney graft preservation study comparing HTK with UW and Euro-Collins.

J de Boer1, J De Meester, J M Smits, A F Groenewoud, A Bok, O van der Velde, I I Doxiadis, G G Persijn.   

Abstract

The aim was to evaluate the effect of HTK compared to UW and Euro-Collins (EC) on the initial graft function and long term graft survival in two prospective randomized studies. Only kidneys from heart-beating, kidney-only or kidney + heart donors were eligible for entry. Initial non-function (INF) was defined as the absence of life-sustaining renal function, requiring dialysis treatment on two or more occasions, during the first week after transplantation. To evaluate the contribution of the preservation solutions on INF in relation to other factors, a multivariate, 2-step logistic regression model was used. Randomization was performed between July 1990 and September 1992. The UW-HTK study comprised 342 donors and 611 transplants (UW: 168 donors and 297 transplants, HTK: 174 donors and 314 transplants). In the EC-HTK study 317 donors and 569 transplants were included (EC: 155 donors and 277 transplants, HTK: 162 donors and 292 transplants). INF occurred in 33% of either HTK-(n = 105) or UW-(n = 99) preserved kidneys (P = NS), and in 29% of the HTK-(n = 85) and in 43% of the EC-(n = 119) preserved kidneys (P = 0.001). Multivariate analysis showed no significant influence of the preservation solution on the incidence of INF in the UW-HTK study, but factors contributing to INF were donor age, cause of death, retransplantation, and cold ischemic period. The EC-HTK study showed a significantly higher risk of INF, using EC as preservation, in addition to cold ischemic period and donor quality. The 3-year graft survival of HTK-preserved kidneys was 73%, compared to 68% for UW-preserved kidneys in the UW-HTK study (P = NS); while the 3-year graft survival of HTK preserved kidneys was 70% compared to 67% for EC-preserved kidneys in the EC-HTK study (P = NS). We can conclude that HTK is comparable to UW in its preservative abilities, using kidneys from heart-beating kidney-only donors, whereas EC as renal preservation solution should be avoided.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10654357     DOI: 10.1007/s001470050256

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  6 in total

Review 1.  Machine perfusion in solid organ transplantation: where is the benefit?

Authors:  Helge Bruns; Peter Schemmer
Journal:  Langenbecks Arch Surg       Date:  2014-01-16       Impact factor: 3.445

Review 2.  Delayed graft function in the kidney transplant.

Authors:  A Siedlecki; W Irish; D C Brennan
Journal:  Am J Transplant       Date:  2011-09-19       Impact factor: 8.086

Review 3.  Preservation solutions used during abdominal transplantation: Current status and outcomes.

Authors:  Nicholas Latchana; Joshua R Peck; Bryan A Whitson; Mitchell L Henry; Elmahdi A Elkhammas; Sylvester M Black
Journal:  World J Transplant       Date:  2015-12-24

4.  Outcomes for primary kidney transplantation from donation after Citizens' death in China: a single center experience of 367 cases.

Authors:  Wujun Xue; Puxun Tian; Heli Xiang; Xiaoming Ding; Xiaoming Pan; Hang Yan; Jun Hou; Xinshun Feng; Linjuan Liu; Chenguang Ding; Xiaohui Tian; Yang Li; Jin Zheng
Journal:  BMC Health Serv Res       Date:  2017-04-04       Impact factor: 2.655

5.  Preservation Solutions for Kidney Transplantation: History, Advances and Mechanisms.

Authors:  Yimeng Chen; Jian Shi; Terry C Xia; Renfang Xu; Xiaozhou He; Ying Xia
Journal:  Cell Transplant       Date:  2019-08-26       Impact factor: 4.064

6.  Comparative Effects of Phosphoenolpyruvate, a Glycolytic Intermediate, as an Organ Preservation Agent with Glucose and N-Acetylcysteine against Organ Damage during Cold Storage of Mouse Liver and Kidney.

Authors:  Yoichi Ishitsuka; Yusuke Fukumoto; Yuki Kondo; Mitsuru Irikura; Daisuke Kadowaki; Yuki Narita; Sumio Hirata; Hiroshi Moriuchi; Toru Maruyama; Naotaka Hamasaki; Tetsumi Irie
Journal:  ISRN Pharmacol       Date:  2013-12-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.